In subgroup analysis stratified by clinical variables, including ECOG performance status, PD‐L1 expression, histology, smoking status, and visceral or bone metastasis status, the treatment effect on PFS and OS favored the ICI‐chemo arm over the chemotherapy arm across most subgroups in the tumor‐informed ctDNA+ group (Figure S4A,B, Supporting Information). The gene discussed is CD274; the disease is bone metastasis.